Phase I study of CBA-1205

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225288

Enrollment

Registered

2020-07-21

Start date

2020-07-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumors, Hepatocellular Carcinoma, Malignant Melanoma, Pediatric Cancer

Interventions

investigational material(s) Generic name etc : CBA-1205 INN of investigational material : - Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational materia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - ECOG performance status: <= 1 - Patients with 3 months or longer life expectancy

Exclusion criteria

Exclusion criteria: - Patients who received other investigational drug or immune checkpoint inhibitor within 28 days prior to enrollment - Patients who received anti-cancer drug within 14 days prior to enrollment

Design outcomes

Primary

Measure	Time frame
safety - Dose limiting toxicity - Adverse event	—

Secondary

Measure	Time frame
efficacy pharmacokinetics other - Tumor response - Tumor marker - Serum concentration of CBA-1205 - Serum concentration of anti-CBA-1205 antibody	—

Countries

Japan

Contacts

Public ContactMiseri Tanaka

Chiome Bioscience Inc.

ir@chiome.co.jp+81-3-6383-3561

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026